Income statement
AUD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 95M | 88M | 78M | 66M | 48M |
| Gross Profit | 79M | 80M | 51M | 47M | 35M |
| Operating Income | 46M | 48M | 41M | 33M | 27M |
| EBITDA | 57M | 56M | 42M | 34M | 28M |
| Net Income | 36M | 36M | 31M | 21M | 25M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$7.10
+0.00% today
1Y Change
+5.19%
Window
Jun 25, 2025 → Jun 24, 2026
Coverage: 250 bars · Jun 25, 2025 → Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Clinuvel Pharmaceuticals Ltd. Sponsored ADR (CLVLY) is a Healthcare stock with a market cap of $480.00M and listed on OTC. The stock last traded around $7.10 and up 5.2% across the available one-year price window (Jun 25, 2025 → Jun 24, 2026). Baseline metrics include revenue growth of +7.8%, EPS growth of 0.0%, a dividend yield of 0.5%. What stands out right now is revenue +7.8%, EPS 0.0%, free cash flow +29.6% with operating margin 39.4% and ROIC 11.1%. The dividend is present but secondary, with a yield around 0.5%. Valuation is more restrained than many high-expectation growth names at P/E 14.7 and price/sales 5.0. Stock Foundry combines CLVLY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CLVLY
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CLVLY Max Drawdown
-29.34%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CLVLY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$48.0M
-27.0% YoY
FY Net Income
$24.7M
+18.4% YoY
Free Cash Flow
$18.4M
-53.3% YoY
Revenue Growth
+7.8%
EPS Growth
+0.0%
Gross Margin
63.7%
Net Margin
33.8%
Income statement
AUD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 95M | 88M | 78M | 66M | 48M |
| Gross Profit | 79M | 80M | 51M | 47M | 35M |
| Operating Income | 46M | 48M | 41M | 33M | 27M |
| EBITDA | 57M | 56M | 42M | 34M | 28M |
| Net Income | 36M | 36M | 31M | 21M | 25M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
AUD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 224M | 184M | 24M | 27M | 37M |
| Total Assets | 272M | 231M | 195M | 145M | 109M |
| Total Liabilities | 31M | 28M | 30M | 19M | 10M |
| Shareholder Equity | 241M | 203M | 165M | 126M | 99M |
| Total Debt | 529K | 880K | 1000K | 1M | 1M |
| Net Debt | -224M | -183M | -23M | -26M | -36M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
19M
-51.7% YoY
Capital Expenditures
854K
-96.7% YoY
Free Cash Flow
18M
-53.3% YoY
Key ratios
Gross Margin
63.7%
Operating Margin
39.4%
Net Margin
33.8%
ROE
13.3%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.